Deoxyguanosine kinase (DGUOK) deficiency is a well-known cause of hepatocerebral mitochondrial DNA depletion syndromes, which include a broad spectrum of clinical presentations. Affected patients often develop life-threatening liver failure, but the benefits of liver transplantation (LT) are controversial because of the frequently severe neurological involvement due to the underlying mitochondrial disease. We describe the long-term clinical course of 2 patients from our institution and provide an update on their outcomes after LT with this condition. Another 12 pediatric patients were identified through a systematic search of the literature. All 14 reported patients underwent transplantation in infancy despite mild to moderate neurological impairment in some cases. The 2 DGUOK-deficient patients from our center displayed liver failure and mild to moderate neurological involvement. At the time of this writing, they had been followed for 5 and 8 years after LT, both patients were alive, and they had only mild neurological symptoms. Three of the 12 patients identified through the literature review survived for a long time (17, 12, and 23 years); 8 died during early follow-up; and for 1 patient, no follow-up information was available. The 1-year survival rate was 64%; 36% survived for more than 5 years. The long-term survivors had good quality of life. In conclusion, although survival after LT for DGUOK deficiency is lower than survival after LT for other indications, a significant proportion of patients benefit from LT with long-term survival and a stable neurological situation despite initial neurological abnormalities. Nevertheless, a decision to carry out LT for patients with DGUOK deficiency remains difficult because neurological symptoms may occur and worsen after LT despite their absence before transplantation.

Download full-text PDF

Source
http://dx.doi.org/10.1002/lt.23830DOI Listing

Publication Analysis

Top Keywords

dguok deficiency
12
patients
9
liver transplantation
8
deoxyguanosine kinase
8
liver failure
8
neurological involvement
8
patients identified
8
mild moderate
8
moderate neurological
8
neurological symptoms
8

Similar Publications

: Deoxyguanosine Kinase (DGUOK) deficiency is a very rare disorder characterized by liver dysfunction, neurological manifestations, and metabolic disorders secondary to severely reduced mitochondrial DNA content. These patients develop early-onset liver failure, and their liver transplantation (LT) indication remains debatable due to the possibility of neurological involvement. : We present the case of a 6-month-old female diagnosed with DGUOK deficiency who developed liver failure.

View Article and Find Full Text PDF

Natural history of deoxyguanosine kinase deficiency.

Mol Genet Metab

October 2024

Department of Metabolic Medicine, Great Ormond Street Hospital, Great Ormond Street, London WC1N 3JH, United Kingdom; UCL Great Ormond Street Institute of Child Health, 30 Guilford Street, London WC1N 1EH, United Kingdom. Electronic address:

Article Synopsis
  • Deoxyguanosine kinase deficiency is a genetic disorder that causes mitochondrial DNA depletion syndrome with three main symptoms: hepatocerebral disease, isolated liver disease, and myopathy.
  • In a study reviewing 173 cases, most patients experienced severe neonatal/infantile-onset hepatocerebral disease, with a grim one-year survival rate of just 11%, and high risk of death associated with certain genetic variants.
  • The research highlights the urgency for early intervention, as the disease progresses rapidly, indicated by a median onset age of 1 month and median death age of 6.5 months for the most severe phenotype.
View Article and Find Full Text PDF

Porto-sinusoidal vascular disorder (PSVD) is a rare liver disease. The pathophysiological mechanisms underlying the development of PSVD are unknown. Isolated cases of PSVD associated with gene mutations have been reported, but no overview is available.

View Article and Find Full Text PDF

Autosomal recessive pathogenetic variants in the gene cause deficiency of deoxyguanosine kinase activity and mitochondrial deoxynucleotides pool imbalance, consequently, leading to quantitative and/or qualitative impairment of mitochondrial DNA synthesis. Typically, patients present early-onset liver failure with or without neurological involvement and a clinical course rapidly progressing to death. This is an international multicentre study aiming to provide a retrospective natural history of deoxyguanosine kinase deficient patients.

View Article and Find Full Text PDF

Nucleoside supplements as treatments for mitochondrial DNA depletion syndrome.

Front Cell Dev Biol

April 2024

Nuffield Department of Women's and Reproductive Health, University of Oxford, Oxford, United Kingdom.

Article Synopsis
  • Mitochondrial DNA depletion syndrome (MDS) is a condition where patients struggle to make enough energy because they lack proper mitochondrial DNA (mtDNA).
  • There’s no cure for MDS yet, but scientists are testing new treatments with special nucleoside supplements to see if they can help boost mtDNA levels in cells.
  • In experiments, one specific combination of nucleosides called ATGC worked really well at helping increase mtDNA in certain cells after being depleted, although higher doses caused some toxic effects.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!